Cargando…
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. Although the risk factors for MPM are well-known, the majority of MPM patients are diagnosed at an advanced stage and have a very poor prognosis. Circulating biomarkers for early diagnosis remain to be identifie...
Autores principales: | Cavallari, Ilaria, Urso, Loredana, Sharova, Evgeniya, Pasello, Giulia, Ciminale, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705182/ https://www.ncbi.nlm.nih.gov/pubmed/31475103 http://dx.doi.org/10.3389/fonc.2019.00740 |
Ejemplares similares
-
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
por: Urso, Loredana, et al.
Publicado: (2019) -
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017) -
Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
por: Cavallari, Ilaria, et al.
Publicado: (2023) -
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
por: Pezzuto, Federica, et al.
Publicado: (2021) -
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data
por: Pasello, Giulia, et al.
Publicado: (2015)